ESTIMATION OF ENZYME (MMP9) IN SALIVA OF OSMF,LEUKOPLAKIA AND CONTROLS
- Conditions
- Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx
- Registration Number
- CTRI/2020/06/026102
- Lead Sponsor
- Akshaya
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Individuals willing to take part in the study
Subjects who are clinically and histopathologically diagnosed with Oral leukoplakia.
Subjects who are clinically diagnosed with OSMF.
Healthy individuals free from systemic illness.
Healthy individuals free from systemic illness and willing to take part in the study are included in control group.
1.Patients with oral cancer
2.Previously treated potentially malignant disorders like oral leukoplakia, OSMF and lichen planus.
3.Having history of significant psychosis/ cognitive impairment
4.Patients with salivary gland disorders causing xerostomia.
5.Patient with acute illness or terminally ill patients.
6.Pregnant women and lactating mother.
7.Patients with systemic diseases which include diabetes, rheumatoid arthritis and hypertension which alter MMP 9 levels.
8.Patients on long term steroid therapy.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method There is increase in the salivary level of MMP-9 in OSMF, Oral leukoplakia and controlsTimepoint: AFTER RUNNING SAMPLE IN ELISA
- Secondary Outcome Measures
Name Time Method salivary levels of MMP-9 as diagnostic biomarkers for patients with Oral leukoplakia and OSMFTimepoint: AFTE RUNNING SAMPLE IN ELISA